1. Apoptosis
    Immunology/Inflammation
  2. TNF Receptor
    Apoptosis
    Interleukin Related
    Caspase
  3. Golimumab

Golimumab (Synonyms: CNTO-148)

Cat. No.: HY-P99111 Purity: 99.68%

Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research.

For research use only. We do not sell to patients.

Golimumab Chemical Structure

Golimumab Chemical Structure

CAS No. : 476181-74-5

Size Price Stock Quantity
1 mg USD 370 In-stock
Estimated Time of Arrival: December 31
5 mg USD 850 In-stock
Estimated Time of Arrival: December 31
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • Customer Review

Description

Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research[1][2][3].

IC50 & Target[1]

CD40

 

In Vitro

Golimumab (CNTO-148) (0.1-10 μg /mL; 24-72 hours; transmembrane TNFα–transfected Jurkat cells) induces reductions in the viability of transmembrane TNFα–expressing cells[1].
Golimumab (CNTO-148) (10 μg /mL; 48 hours; transmembrane TNFα–transfected Jurkat cells) induces apoptosis, increase the levels of active caspase-3 and induces apoptotic DNA fragmentation[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Transmembrane TNFα–transfected Jurkat cells
Concentration: 0.1, 1 and 10 μg/mL
Incubation Time: 24, 48 and 72 hours
Result: Reduced cell viability in a dose- and time-dependent manner.

Apoptosis Analysis[1]

Cell Line: Transmembrane TNFα–transfected Jurkat cells
Concentration: 10 μg /mL
Incubation Time: 48 hours
Result: Had the percentage of apoptotic cells for 30.29%.

Western Blot Analysis[1]

Cell Line: Transmembrane TNFα–transfected Jurkat cells
Concentration: 10 μg /mL
Incubation Time: 48 hours
Result: Increased the levels of active caspase-3 and induces apoptotic DNA fragmentation.
In Vivo

Golimumab (CNTO-148) (24 mg/kg; i.h.; daily, for 7 days; swiss-albino healthy male mice) inhibits oxidative stress, apoptotic cell death inflammatory response, thus improving renal function. Golimumab reduces all markers of kidney injury and attenuates cell death[2].
Golimumab (CNTO-148) (1-10 mg/kg; i.p.;daily; for 4 weeks; Tg197 transgenic mouse model) relieves TNFα-induced arthritis in a mouse model of human[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Swiss-albino healthy male mice[2]
Dosage: 24 mg/kg
Administration: Subcutaneous injection; daily, for 7 days
Result: Reduced serum parameters like BUN, NGAL creatinine, cystatin C, and urinary parameters like KIM-1, NAG, albumin clusterin.
Animal Model: Swiss-albino healthy male mice[2]
Dosage: 24 mg/kg
Administration: Subcutaneous injection; daily, for 7 days
Result: Inhibited oxidative stress, reduces MDA concentrations and increases the GSH and catalase levels.
Animal Model: Swiss-albino healthy male mice[2]
Dosage: 24 mg/kg
Administration: Subcutaneous injection; daily, for 7 days
Result: Inhibitd cisplatin-induced inflammation, decreased TNF-α, including IL-6, IL-1β, MCP-1, ICAM-1, and TGF-β1 levels and increases IL-10 concentrations, reduced caspase 3 in cisplatin injected mice kidneys.
Animal Model: Tg197 transgenic mouse model[3]
Dosage: 1 and 10 mg/kg
Administration: Intraperitoneal injection;for 4 weeks
Result: Reduced the arthritic index.
CAS No.
SMILES

[Golimumab]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Purity: 99.68%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Golimumab
Cat. No.:
HY-P99111
Quantity:
MCE Japan Authorized Agent: